AbbVie announced the presentation of 20 new scientific abstracts at the 2026 United European Gastroenterology Week, highlighting positive long-term data for its key inflammatory bowel disease (IBD) treatments, Skyrizi and Rinvoq. The data demonstrated sustained clinical and endoscopic improvements for patients with Crohn's disease and ulcerative colitis over periods of up to four years, reinforcing the drugs' efficacy and safety profiles.
The comprehensive data set underscores AbbVie's leadership in the IBD space and the successful transition of its immunology portfolio beyond its former blockbuster, Humira. The continued strong performance and positive clinical data for Skyrizi and Rinvoq are crucial for the company's revenue growth. Some market commentary noted strong investor interest and a recent increase in AbbVie's stock price around the time of the announcement.